Immuneering appoints Scott Barrett as chief medical officer
Dr. Barrett brings nearly three decades of experience as a board-certified medical oncologist, clinical researcher and industry executive.
Prior to joining Immuneering, Dr. Barrett was the global medical affairs lead for Targeted Therapeutics at Incyte Pharmaceuticals, where he oversaw the strategic development of the company’s pipeline of targeted anti-cancer agents across both early and registrational-stage clinical trials.
Before Incyte, Dr. Barrett served as senior director of clinical development for Infinity Pharmaceuticals Inc., where he provided strategic direction to the clinical team of on-study treatment for patients with relapsed/refractory, indolent non-Hodgkin’s lymphoma.
Additionally, he served as medical monitor and clinical oncology lead for all of Infinity’s NHL studies.
Prior to Infinity, Dr. Barrett was director of clinical development of the Oncology Product Creations Unit for Eisai Pharmaceuticals Inc., and also served as the medical director of Oncology for Janssen Division of Johnson and Johnson Inc.
Prior to his industry experience, Dr. Barrett spent 15 years treating patients as a senior partner of academic group practices affiliated with Beth Israel Hospital in New York, N.Y., Crouse Memorial Hospital in Syracuse, N.Y. and James P. Wilmot Cancer Center of Strong Memorial Hospital in Rochester, N.Y.
Dr. Barrett earned his Bachelor of Arts in natural sciences as a Beneficial Hodson scholar from Johns Hopkins University in Baltimore, Md.
Following his bachelor’s degree, he earned his medical degree from the University of Miami School of Medicine.
He then completed his residency in internal medicine at the Mayo Clinic in Rochester, Minn. ■